How diabesity is shaping the world of self-injection devices

Innovative peptide hormone molecules for treating diabetes and obesity are fundamentally changing the market for self-injection systems and the demand for pens and autoinjectors continues to increase.

YpsoDose – The clinical ready 10mL patch injector

Christian Esser Wiesemann provides the latest insights into the YpsoDose pre-filled and pre-assembled patch injector which is available for clinical trials.

Welcome to Ypsomed Pulse – Your pathway to selfcare insights

In our new blog “Ypsomed Pulse”, we want to share expertise and knowledge with our customers, partners, and other players in and around the industry because we believe in the benefit of collective growth and progress.

​​Breaking barriers: Understanding the potential of large-volume autoinjectors​

Immerse yourself in the future of subcutaneous drug administration with large-volume autoinjectors. Our comprehensive literature review reveals their transformative potential to break barriers in delivering single large-volume doses.

Milestones in manufacturing: Mastering UnoPen and YpsoPen success

UnoPen and YpsoPen are two of Ypsomed’s platforms developed and customized on behalf of various pharma customers for patients dependent on insulin but also GLP-1, hGH, FSH and PTH. Demand for these devices has now exceeded the total of 100 million UnoPen and 10 million YpsoPen delivered units.